The University of Southampton
University of Southampton Institutional Repository

Open innovation in the UK biopharmaceutical industry: a multi-layered investigation

Open innovation in the UK biopharmaceutical industry: a multi-layered investigation
Open innovation in the UK biopharmaceutical industry: a multi-layered investigation
Whilst the interest in open innovation is growing, thus far few studies have emphasised its importance beyond hi-tech industries and large multinationals. This research aims to generate an understanding of open innovation adoption within the UK Bio-pharmaceutical industry, which is chosen because of the significant growth it has experienced in recent times, and is heavy reliance on R&D. The findings of this multi-level study present a holistic view of the opportunities and barriers pertaining to open innovation in Biopharmaceutical SMEs and large firms, as well as indicating that open innovation strategies assist firms’ in terms of value creation and capture. The study also illustrates that strategies cannot necessarily be regarded as explicitly open or closed innovation, as there is a significant spectrum of approaches in the space between.

The study’s theoretical contribution develops the use of critical realism, a scientific reality which is not only about constant combinations of observable events but is also about individuals, entities and structures that exist and generate the events we witness and observe. In doing so, the study utilises an alternative to inductive or deductive reasoning, the retroductive reasoning. Through retroduction, the study to explain these causal powers, mechanisms, as well as the contingent relations of individuals that are responsible for the creation of a firm’s strategic considerations based on a multi-layered approach (micro-with individuals/meso-with various organisations/macro-with various government bodies and organisations).

The study comprises three sets of results, focusing on CEOs, knowledge brokers and senior executives respectively. The first set of results, based on 30 interviews of CEOs in Small-to-Medium sized Enterprises (SMEs), suggests that i
open innovation practices are utilised in a multi-level, but that not all SMEs adopt the open concept. This shows the reluctance of CEOs in SMEs in sharing internal information and intellectual property. The second set, obtained from interviews with 8 Knowledge Brokers in the industry, emphasised the need for an agenda when open practices are utilised and there are personal preconceptions regarding business, which are in many cases difficult to change or adjust during open approaches. The third set, obtained from a survey questionnaire with 12 executives of 10 large biopharmaceutical firms, illustrates the importance their firms place on open innovation practices, particularly in collaborating with various firms and organisations.

In spite of the industry’s recent efforts, the study identifies that benefits from the adoption of open innovation are yet to be seen, as the realisation of research and development outcomes within the Biopharmaceutical sector is a long process. Furthermore, the study clarifies that open innovation is not a monopoly of large firms in the high-tech sector, but can be adopted in various other firms in different industries.

Additionally, this study contributes to the expansion of multi-layered approaches, as they give a thorough view of the processes that are involved during open innovation adoption. Finally, the research addresses the lack of empirical work in open innovation and suggests methods that identify how and why particular processes are utilised when open strategies are adopted, and elucidates the space between closed and open innovation.
Marangos, Stefanos
b1f9a584-8ad8-4dc4-a38a-9078d095f530
Marangos, Stefanos
b1f9a584-8ad8-4dc4-a38a-9078d095f530
WARREN, LORRAINE
1ec8193d-f90f-48f6-9205-041dcf89121d

Marangos, Stefanos (2014) Open innovation in the UK biopharmaceutical industry: a multi-layered investigation. University of Southampton, School of Management, Doctoral Thesis, 357pp.

Record type: Thesis (Doctoral)

Abstract

Whilst the interest in open innovation is growing, thus far few studies have emphasised its importance beyond hi-tech industries and large multinationals. This research aims to generate an understanding of open innovation adoption within the UK Bio-pharmaceutical industry, which is chosen because of the significant growth it has experienced in recent times, and is heavy reliance on R&D. The findings of this multi-level study present a holistic view of the opportunities and barriers pertaining to open innovation in Biopharmaceutical SMEs and large firms, as well as indicating that open innovation strategies assist firms’ in terms of value creation and capture. The study also illustrates that strategies cannot necessarily be regarded as explicitly open or closed innovation, as there is a significant spectrum of approaches in the space between.

The study’s theoretical contribution develops the use of critical realism, a scientific reality which is not only about constant combinations of observable events but is also about individuals, entities and structures that exist and generate the events we witness and observe. In doing so, the study utilises an alternative to inductive or deductive reasoning, the retroductive reasoning. Through retroduction, the study to explain these causal powers, mechanisms, as well as the contingent relations of individuals that are responsible for the creation of a firm’s strategic considerations based on a multi-layered approach (micro-with individuals/meso-with various organisations/macro-with various government bodies and organisations).

The study comprises three sets of results, focusing on CEOs, knowledge brokers and senior executives respectively. The first set of results, based on 30 interviews of CEOs in Small-to-Medium sized Enterprises (SMEs), suggests that i
open innovation practices are utilised in a multi-level, but that not all SMEs adopt the open concept. This shows the reluctance of CEOs in SMEs in sharing internal information and intellectual property. The second set, obtained from interviews with 8 Knowledge Brokers in the industry, emphasised the need for an agenda when open practices are utilised and there are personal preconceptions regarding business, which are in many cases difficult to change or adjust during open approaches. The third set, obtained from a survey questionnaire with 12 executives of 10 large biopharmaceutical firms, illustrates the importance their firms place on open innovation practices, particularly in collaborating with various firms and organisations.

In spite of the industry’s recent efforts, the study identifies that benefits from the adoption of open innovation are yet to be seen, as the realisation of research and development outcomes within the Biopharmaceutical sector is a long process. Furthermore, the study clarifies that open innovation is not a monopoly of large firms in the high-tech sector, but can be adopted in various other firms in different industries.

Additionally, this study contributes to the expansion of multi-layered approaches, as they give a thorough view of the processes that are involved during open innovation adoption. Finally, the research addresses the lack of empirical work in open innovation and suggests methods that identify how and why particular processes are utilised when open strategies are adopted, and elucidates the space between closed and open innovation.

PDF
Marangos, Stefanos final thesis.pdf - Other
Download (5MB)

More information

Published date: June 2014
Organisations: University of Southampton, Southampton Business School

Identifiers

Local EPrints ID: 367815
URI: http://eprints.soton.ac.uk/id/eprint/367815
PURE UUID: 2379808a-69a5-4252-9127-bf109034c779

Catalogue record

Date deposited: 24 Oct 2014 10:24
Last modified: 18 Jul 2017 01:55

Export record

Contributors

Author: Stefanos Marangos
Thesis advisor: LORRAINE WARREN

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×